Accession Number : AD1004089


Title :   Loss of PEDF: A Novel Mechanism of Antihormone Resistance in Breast Cancer


Descriptive Note : Technical Report,01 Aug 2012,31 Jul 2015


Corporate Author : University of Kansas Medical Center Kansas City United States


Personal Author(s) : Lewis-Wambi,Joan


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1004089.pdf


Report Date : 01 Oct 2015


Pagination or Media Count : 88


Abstract : Resistance to endocrine therapy such as tamoxifen or aromatase inhibitors is a major clinical obstacle to the effective treatment and cure of women with estrogen receptor (ER)-positive breast cancer. It is estimated that 40% of breast cancer patients will develop endocrine-resistant disease following long-term treatment. The possibility of identifying new targets for therapy in resistant disease, or patients, who may benefit from additional treatment with existing therapies, provides a strong impetus to identify markers and mediators of therapeutic resistance. Our laboratory has identified a novel protein called pigment epithelium derived factor (PEDF) that appears to be suppressed/silenced in endocrine resistant breast cancer.


Descriptors :   breast cancer , cells(biology) , MOLECULAR PROPERTIES


Distribution Statement : APPROVED FOR PUBLIC RELEASE